On the other hand, a claudin 1-based antibody drug conjugate may be more appropriate for use in CMS2 colon cancers, which express higher levels of the target, thus helping to direct the cytotoxic moiety to the cancer cells. The gene discussed is CLDN1; the disease is cancer.